Abstract
BackgroundSeveral medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic. Therefore, the aim was to assess whether there is an association between therapeutic interventions and malignancies in JIA patients.FindingsA nested case–control study was carried out within a retrospective cohort study of 3698 JIA patients diagnosed between 1952 and 2010. All 48 JIA patients with a diagnosis of a malignant tumour and up to four matched controls for each received a questionnaire about their use of medication. Subsequently treatment was compared between cases and controls and analyses performed for 37 cases and 125 controls (response 88.5 %). Treatment with DMARD (84 %) was most frequently used, followed by glucocorticoids (66 %) and immunosuppressives (65 %). Twenty percent reported to have ever been taking biologics. Medication use did not differ significantly between cases and controls.ConclusionsOur results did not show an association between medications used and malignancies in JIA patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12969-016-0066-8) contains supplementary material, which is available to authorized users.
Highlights
Several medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic
Our results did not show an association between medications used and malignancies in JIA patients
This study carried out a retrospective cohort study on cancer incidence in 3692 JIA patients (Barth S, Schlichtiger J, Hartmann B, Bisdorff B, Michels H, Radon K et al Incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a retrospective singlecentre cohort study,submitted.) Nested within this retrospective cohort study, a case–control study to investigate whether type of treatment differed between JIA patients with and without cancer was performed
Summary
Patients with Juvenile Idiopathic Arthritis (JIA) are considered to be at higher risk of malignancies than the general population [1]. Potential explanations for this increased risk might be the inflammatory process underlying the disease [2], frequent use of diagnostic procedures involving exposure to ionizing radiation [3] or therapeutic interventions [1]. This study carried out a retrospective cohort study on cancer incidence in 3692 JIA patients (Barth S, Schlichtiger J, Hartmann B, Bisdorff B, Michels H, Radon K et al Incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a retrospective singlecentre cohort study,submitted.) Nested within this retrospective cohort study, a case–control study to investigate whether type of treatment differed between JIA patients with and without cancer was performed. Chloroquine, cyclosporine a, D-penicillamine, etanercept, hydroxychloroquine, infliximab, leflunomide, methotrexate, mycophenolatmofetil, natriumaurothiomalate, oral cortisone, rituximab, sulfasalazine, tocilizumab), – If a specific type of drug was taken, duration of intake was requested (2 years), – Potential other risk factors of cancer (parental cancer history, computed tomography (CT), x-ray, scintigraphy, nuclear radiation therapy)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
